Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Длительная терапия низкими дозами макролидов при хроническом риносинусите: зарубежный опыт и собственный взгляд
Длительная терапия низкими дозами макролидов при хроническом риносинусите: зарубежный опыт и собственный взгляд
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Балмасова И.П., Еремина О.Ф., Гультяев М.М. и др. Иммунологические и аллергологические аспекты клинического применения макролидов. Рос. аллергол. журн. 2007; 3: 12–9.
2. Bachert C, Wagenmann M, Rudack C et al. The role of cytokines in infectious sinusitis and nasal polyposis. Allergy 1998; 53: 2–13.
3. Сervin A, Kalm O, Sandkull P et al. One-year low-dose erythromycin treatment of persistent chronic sinusitis after sinus surgery: clinical outcome and effect on mucociliary parameters and nasal nitric oxide. Otolaryngol Head Neck Surg 2002; 126: 481–9.
4. Cervin A, Wallwork B. Macrolide therapy of chronic rhinosinusitis. Rhinology 2007; 45 (4): 259–67.
5. Cervin A, Wallwork B, Mackay-Sim A et al. Effects of long-term clarithromycin treatment on lavage-fluid markers of inflammation in chronic rhinosinusitis. Clin Phys Funct Imag 2009; 29 (2): 136–42.
6. Desaki M, Takizawa H, Otoshi T et al. Erythromycin suppresses nuclear factor-kappa B and activator protein-1 activation in human bronchial epithelial cells. Biochem Biophys Res Commun 2000; 267: 286–90.
7. Desrosiers MY, Kilty SJ. Treatment alternatives for chronic rhinosinusitis persisting after ESS: what to do when antibiotics, steroids and surgery fail. Rhinology 2008; 46 (1): 3–14.
8. EP3OS Primary Care Guidelines: European Position Paper on the Primary Care Diagnosis and Management of Rhinosinusitis and nasal Polyps 2007 – a summary. Prim Care Resp J 2008; 17 (2): 79–89.
9. Hashiba M, Baba S. Efficacy of long-term administration of Clarythromycin in the treatment of intractable chronic sinusitis. Acta Otolaryngol 1996; 525 (Suppl.): 73–8.
10. Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010; 23 (3): 590–615.
11. Labro MT. Cellular ffects of macrolides on leukocyte function. Current pharmaceutical design 2004; 10: 3067–80.
12. Lino Y, Sugita K, Toriyama M et al. Erythromycin therapy for otitis media with effusion in sinobronchial syndrome. Arch Otolaryngol Head Neck Surg 1993; 119: 648–51.
13. Nalca Y, Jänsch L, Geffers R еt al. Quorum-Sensing Antagonistic Activities of Azithromycin in Pseudomonas aeruginosa PAO1: a Global Approach. Antimicrob Agents Chemother 2006; 50: 1680–8.
14. Ponikau J, Sherris D, Weaver A еt al. Treatment of chronic rhinosinusitis with intranasal amphotericin B: A randomized, placebo-controlled, double-blind pilot trial. J Allergy Clin Immunology 2005; 115 (1): 125–31.
15. Rhee CS, Majima Y, Arima S et al. Effects of clarithromycin on rheological properties of nasal mucus in patients with chronic. Ann Otol Rhinol Laryngol 2000; 109: 484–7.
16. Rubin BK, Druce H, Ramires OE et al. Effect of Clarithromycin on nasal mucus properties in healthy sudjects and in patients with purulent rhinitis. Am J Respir Crit Care Med 1997; 155: 2018–23.
17. Scavuzzo M, Fattori B, Ruffoli R et al. Inflammatory mediators and eosinophilia in atopic and non-atopic patients with nasal polyposis. Biomed Pharmacother 2005; 59 (6): 323–9.
18. Wallwork B, Coman W, Mackay-Sim A et al. Effect of Clarithromycin on Nuclear Factor-KB and Transforming Growth Factor-B in Chronic Rhinosinusitis. Laryngoscope 2004; 114: 286–90.
19. Wozniak DJ, Keyser R. Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Chest 2004; 125: 62S–9S.
2. Bachert C, Wagenmann M, Rudack C et al. The role of cytokines in infectious sinusitis and nasal polyposis. Allergy 1998; 53: 2–13.
3. Сervin A, Kalm O, Sandkull P et al. One-year low-dose erythromycin treatment of persistent chronic sinusitis after sinus surgery: clinical outcome and effect on mucociliary parameters and nasal nitric oxide. Otolaryngol Head Neck Surg 2002; 126: 481–9.
4. Cervin A, Wallwork B. Macrolide therapy of chronic rhinosinusitis. Rhinology 2007; 45 (4): 259–67.
5. Cervin A, Wallwork B, Mackay-Sim A et al. Effects of long-term clarithromycin treatment on lavage-fluid markers of inflammation in chronic rhinosinusitis. Clin Phys Funct Imag 2009; 29 (2): 136–42.
6. Desaki M, Takizawa H, Otoshi T et al. Erythromycin suppresses nuclear factor-kappa B and activator protein-1 activation in human bronchial epithelial cells. Biochem Biophys Res Commun 2000; 267: 286–90.
7. Desrosiers MY, Kilty SJ. Treatment alternatives for chronic rhinosinusitis persisting after ESS: what to do when antibiotics, steroids and surgery fail. Rhinology 2008; 46 (1): 3–14.
8. EP3OS Primary Care Guidelines: European Position Paper on the Primary Care Diagnosis and Management of Rhinosinusitis and nasal Polyps 2007 – a summary. Prim Care Resp J 2008; 17 (2): 79–89.
9. Hashiba M, Baba S. Efficacy of long-term administration of Clarythromycin in the treatment of intractable chronic sinusitis. Acta Otolaryngol 1996; 525 (Suppl.): 73–8.
10. Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010; 23 (3): 590–615.
11. Labro MT. Cellular ffects of macrolides on leukocyte function. Current pharmaceutical design 2004; 10: 3067–80.
12. Lino Y, Sugita K, Toriyama M et al. Erythromycin therapy for otitis media with effusion in sinobronchial syndrome. Arch Otolaryngol Head Neck Surg 1993; 119: 648–51.
13. Nalca Y, Jänsch L, Geffers R еt al. Quorum-Sensing Antagonistic Activities of Azithromycin in Pseudomonas aeruginosa PAO1: a Global Approach. Antimicrob Agents Chemother 2006; 50: 1680–8.
14. Ponikau J, Sherris D, Weaver A еt al. Treatment of chronic rhinosinusitis with intranasal amphotericin B: A randomized, placebo-controlled, double-blind pilot trial. J Allergy Clin Immunology 2005; 115 (1): 125–31.
15. Rhee CS, Majima Y, Arima S et al. Effects of clarithromycin on rheological properties of nasal mucus in patients with chronic. Ann Otol Rhinol Laryngol 2000; 109: 484–7.
16. Rubin BK, Druce H, Ramires OE et al. Effect of Clarithromycin on nasal mucus properties in healthy sudjects and in patients with purulent rhinitis. Am J Respir Crit Care Med 1997; 155: 2018–23.
17. Scavuzzo M, Fattori B, Ruffoli R et al. Inflammatory mediators and eosinophilia in atopic and non-atopic patients with nasal polyposis. Biomed Pharmacother 2005; 59 (6): 323–9.
18. Wallwork B, Coman W, Mackay-Sim A et al. Effect of Clarithromycin on Nuclear Factor-KB and Transforming Growth Factor-B in Chronic Rhinosinusitis. Laryngoscope 2004; 114: 286–90.
19. Wozniak DJ, Keyser R. Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Chest 2004; 125: 62S–9S.
Авторы
А.В.Варвянская1, А.С.Лопатин1, К.А.Зыков2
1 Кафедра болезней уха, горла и носа Первого МГМУ им. И.М.Сеченова
2 Лаборатория пульмонологии НИМСИ МГМСУ
1 Кафедра болезней уха, горла и носа Первого МГМУ им. И.М.Сеченова
2 Лаборатория пульмонологии НИМСИ МГМСУ
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.